210 related articles for article (PubMed ID: 36863753)
1. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
van der Togt CJT; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36863753
[TBL] [Abstract][Full Text] [Related]
2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
[TBL] [Abstract][Full Text] [Related]
6. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
7. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
Nagy G; Roodenrijs NMT; Welsing PMJ; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Pchelnikova P; Blaas E; Senolt L; Szekanecz Z; Choy EH; Dougados M; Jacobs JW; Geenen R; Bijlsma JW; Zink A; Aletaha D; Schoneveld L; van Riel P; Dumas S; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
Ann Rheum Dis; 2022 Jan; 81(1):20-33. PubMed ID: 34407926
[TBL] [Abstract][Full Text] [Related]
8. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
9. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
[TBL] [Abstract][Full Text] [Related]
10. EULAR definition of difficult-to-treat rheumatoid arthritis.
Nagy G; Roodenrijs NMT; Welsing PM; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Blaas E; Senolt L; Szekanecz Z; Choy E; Dougados M; Jacobs JW; Geenen R; Bijlsma HW; Zink A; Aletaha D; Schoneveld L; van Riel P; Gutermann L; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
Ann Rheum Dis; 2021 Jan; 80(1):31-35. PubMed ID: 33004335
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
14. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
17. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Krieckaert CL; van Tubergen A; Gehin JE; Hernández-Breijo B; Le Mélédo G; Balsa A; Böhm P; Cucnik S; Elkayam O; Goll GL; Hooijberg F; Jani M; Kiely PD; McCarthy N; Mulleman D; Navarro-Compán V; Payne K; Perry ME; Plasencia-Rodriguez C; Stones SR; Syversen SW; de Vries A; Ward KM; Wolbink G; Isaacs JD
Ann Rheum Dis; 2023 Jan; 82(1):65-73. PubMed ID: 35551063
[TBL] [Abstract][Full Text] [Related]
18. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2022 Jan; 18(1):33-41. PubMed ID: 35090610
[TBL] [Abstract][Full Text] [Related]
19. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
20. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Colebatch AN; Marks JL; Edwards CJ
Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
